Close

Canaccord Genuity Starts Halozyme Therapeutics (HALO) at Buy

February 1, 2016 7:54 AM EST
Get Alerts HALO Hot Sheet
Price: $40.73 --0%

Rating Summary:
    16 Buy, 5 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 10
Join SI Premium – FREE

Canaccord Genuity initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $8.80 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Canaccord Genuity